Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Lewiecki, E. Michael [1 ]
Dinavahi, Rajani V. [2 ]
Lazaretti-Castro, Marise [3 ]
Ebeling, Peter R. [4 ]
Adachi, J. [5 ]
Miyauchi, Akimitsu [6 ]
Gielen, Evelien [7 ]
Milmont, Cassandra E. [2 ]
Libanati, Cesar [8 ]
Grauer, Andreas [2 ]
机构：
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Monash Univ, Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON, Canada
[6] Miyauchi Med Ctr, Osaka, Japan
[7] Univ Hosp Leuven, Leuven, Belgium
[8] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSOZUMAB VS. ALENDRONATE TREATMENT IN THE ACTIVE-CONTROLLED FRACTURE STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK TRIAL
    Cosman, F.
    Lewiecki, E. M.
    Ebeling, P. R.
    Hesse, E.
    Napoli, N.
    Crittenden, D. B.
    Rojeski, M.
    Yang, W.
    Libanati, C.
    Ferrari, S. L.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S168 - S168
  • [32] Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
    Saag, Kenneth G.
    de Villiers, Tobie
    Alexandersen, Peter
    Jacobe, Heidi
    Kovarik, Carrie
    Werth, Victoria P.
    Leung, Albert
    Desai-Merchant, Avani
    Mattaliano, Julie
    Gurner, Deborah
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [33] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial
    Ettinger, B
    Black, DM
    Mitlak, BH
    Knickerbocker, RK
    Nickelsen, T
    Genant, HK
    Christiansen, C
    Delmas, PD
    Zanchetta, JR
    Stakkestad, J
    Glüer, CC
    Krueger, K
    Cohen, FJ
    Eckert, S
    Ensrud, KE
    Avioli, LV
    Lips, P
    Cummings, SR
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07): : 637 - 645
  • [34] Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study
    Kushida, K
    Shiraki, M
    Nakamura, T
    Kishimoto, H
    Morii, H
    Yamamoto, K
    Kaneda, K
    Fukunaga, M
    Inoue, T
    Nakashima, M
    Orimo, H
    JOURNAL OF BONE AND MINERAL METABOLISM, 2004, 22 (05) : 462 - 468
  • [35] Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study
    Kazuhiro Kushida
    Masataka Shiraki
    Toshitaka Nakamura
    Hideaki Kishimoto
    Hirotoshi Morii
    Kichizo Yamamoto
    Kiyoshi Kaneda
    Masao Fukunaga
    Tetsuro Inoue
    Mitsuyoshi Nakashima
    Hajime Orimo
    Journal of Bone and Mineral Metabolism, 2004, 22 : 462 - 468
  • [36] Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
    Brown, Jacques P.
    Engelke, Klaus
    Keaveny, Tony M.
    Chines, Arkadi
    Chapurlat, Roland
    Foldes, A. Joseph
    Nogues, Xavier
    Civitelli, Roberto
    De Villiers, Tobias
    Massari, Fabio
    Zerbini, Cristiano A. F.
    Wang, Zhenxun
    Oates, Mary K.
    Recknor, Christopher
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (11) : 2139 - 2152
  • [37] Prediction of fracture risk in 5195 postmenopausal women from Spain by quantitative ultrasound of the calcaneus:: 18 months interim results from the ECOSAP prospective study
    González-Macías, J
    Marín, F
    Vila, J
    Martín, D
    Alfonso, C
    Benavides, P
    Pozuelos, J
    Chavida, F
    Pérez, J
    Granados, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S68 - S68
  • [38] A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk
    Hao Zhang
    Jie-mei Gu
    Ai-jun Chao
    Qun Cheng
    Dong-hui Teng
    Jin-ming Yu
    Bing-wu Wang
    Ya-nan Huo
    Li Mao
    Qiu Zhang
    Hong Yang
    Shi-gui Yan
    Ke-qin Zhang
    Xue-ling Zhao
    Hua Lin
    Yu Pei
    Zhong Yuan
    Ru-chun Dai
    Liang He
    Li Chen
    Yong-feng Su
    Zhong-liang Deng
    Li You
    Bo Ban
    Mei Zhu
    You-liang Cao
    Yi-kun Zhu
    Zhi-jun Li
    Zhi Zhang
    Cheng-qing Yi
    Yi-bing Lu
    Guang Wang
    Cui-cui Han
    Zhen-jiang Wang
    Xian-xing Li
    Zhen-lin Zhang
    Acta Pharmacologica Sinica, 2023, 44 : 446 - 453
  • [39] A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk
    Zhang, Hao
    Gu, Jie-Mei
    Chao, Ai-Jun
    Cheng, Qun
    Teng, Dong-Hui
    Yu, Jin-Ming
    Wang, Bing-Wu
    Huo, Ya-Nan
    Mao, Li
    Zhang, Qiu
    Yang, Hong
    Yan, Shi-Gui
    Zhang, Ke-Qin
    Zhao, Xue-Ling
    Lin, Hua
    Pei, Yu
    Yuan, Zhong
    Dai, Ru-Chun
    He, Liang
    Chen, Li
    Su, Yong-Feng
    Deng, Zhong-Liang
    You, Li
    Ban, Bo
    Zhu, Mei
    Cao, You-Liang
    Zhu, Yi-Kun
    Li, Zhi-Jun
    Zhang, Zhi
    Yi, Cheng-Qing
    Lu, Yi-Bing
    Wang, Guang
    Han, Cui-Cui
    Wang, Zhen-Jiang
    Li, Xian-Xing
    Zhang, Zhen-Lin
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (02) : 446 - 453
  • [40] Erratum to: Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study
    Kazuhiro Kushida
    Masataka Shiraki
    Toshitaka Nakamura
    Hideaki Kishimoto
    Hirotoshi Morii
    Kichizo Yamamoto
    Kiyoshi Kaneda
    Masao Fukunaga
    Tetsuro Inoue
    Mitsuyoshi Nakashima
    Hajime Orimo
    Journal of Bone and Mineral Metabolism, 2005, 23 : 95 - 95
12345